Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity

dc.bibliographicCitation.firstPage1
dc.bibliographicCitation.journalTitleOxidative Medicine and Cellular Longevityeng
dc.bibliographicCitation.lastPage19
dc.bibliographicCitation.volume2021
dc.contributor.authorFaramarzi, Fatemeh
dc.contributor.authorZafari, Parisa
dc.contributor.authorAlimohammadi, Mina
dc.contributor.authorMoonesi, Mohammadreza
dc.contributor.authorRafiei, Alireza
dc.contributor.authorBekeschus, Sander
dc.date.accessioned2023-05-25T10:24:57Z
dc.date.available2023-05-25T10:24:57Z
dc.date.issued2021
dc.description.abstractDespite recent advances in therapy, cancer still is a devastating and life-threatening disease, motivating novel research lines in oncology. Cold physical plasma, a partially ionized gas, is a new modality in cancer research. Physical plasma produces various physicochemical factors, primarily reactive oxygen and nitrogen species (ROS/RNS), causing cancer cell death when supplied at supraphysiological concentrations. This review outlines the biomedical consequences of plasma treatment in experimental cancer therapy, including cell death modalities. It also summarizes current knowledge on intracellular signaling pathways triggered by plasma treatment to induce cancer cell death. Besides the inactivation of tumor cells, an equally important aspect is the inflammatory context in which cell death occurs to suppress or promote the responses of immune cells. This is mainly governed by the release of damage-associated molecular patterns (DAMPs) to provoke immunogenic cancer cell death (ICD) that, in turn, activates cells of the innate immune system to promote adaptive antitumor immunity. The pivotal role of the immune system in cancer treatment, in general, is highlighted by many clinical trials and success stories on using checkpoint immunotherapy. Hence, the potential of plasma treatment to induce ICD in tumor cells to promote immunity targeting cancer lesions systemically is also discussed.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/12185
dc.identifier.urihttp://dx.doi.org/10.34657/11217
dc.language.isoeng
dc.publisherAustin, Tex. : Landes Bioscience
dc.relation.doihttps://doi.org/10.1155/2021/9916796
dc.relation.essn1942-0994
dc.relation.issn1942-0900
dc.rights.licenseCC BY 4.0 Unported
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610
dc.subject.otherCell signalingeng
dc.subject.otherDisease controleng
dc.subject.otherDiseaseseng
dc.subject.otherImmune systemeng
dc.subject.otherIonization of gaseseng
dc.subject.otherNitrogen plasmaeng
dc.subject.otherOncologyeng
dc.subject.otherPlasma applicationseng
dc.subject.otherTumorseng
dc.titleCold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunityeng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccess
wgl.contributorINP
wgl.subjectMedizin, Gesundheitger
wgl.typeZeitschriftenartikelger
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
9916796.pdf
Size:
1.21 MB
Format:
Adobe Portable Document Format
Description:
Collections